Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03526887
Recruitment Status : Recruiting
First Posted : May 16, 2018
Last Update Posted : March 29, 2019
Sponsor:
Information provided by (Responsible Party):
Spanish Lung Cancer Group

Brief Summary:

Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti-PDL1 drug.

Pembrolizumab 200 mg ,Q3W, IV infusion, Day 1 of each 3 week cycle will be administered until disease progression.


Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Pembrolizumab Phase 2

Detailed Description:

This is a multi-center exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti-PDL1 drug.

110 patients will be enrolled in this trial to examine the efficacy and outcomes of these patients.

In addition to the usual procedures in a phase II study (evaluation of response, toxicity, etc.) special attention will be paid in this trial to the molecular assessment in biological samples.

Subjects will receive Pembrolizumab at a fixed dose of 200 mg every 3 weeks (Q3W). Subjects will be evaluated with radiographic imaging to assess response to treatment. Investigators will make all treatment-based decisions using the Immune-Related Response Criteria (irRC). However, for determination of overall response rate (ORR) and progression-free survival (PFS), the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be used.

Adverse events will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment with Pembrolizumab will continue until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, noncompliance with trial treatment or procedure requirements, or administrative reasons.

After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring (serious adverse events will be collected for up to 90 days after the end of treatment unless the subject starts a new anticancer therapy between days 31 and 90). Subjects will have post-treatment follow-up for disease status, including initiating a non-study cancer treatment and experiencing disease progression, until death, withdrawing consent, or becoming lost to follow-up.

Participation in this trial will be dependent upon supplying tumor tissue from a newly obtained formalin-fixed specimen from locations not radiated prior to biopsy. The specimen will be evaluated at a central laboratory facility for expression status of PD-L1 in a prospective manner. Only subjects whose tumors express PD-L1 as determined by the central laboratory facility will be eligible for inclusion in this study. Also it is highly recommend to send archival tumor tissue from the patient.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2 groups depending on when the progression disease is diagnosed but the treatment after progression will be the same: Pembrolizumab
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Actual Study Start Date : July 15, 2018
Estimated Primary Completion Date : July 15, 2022
Estimated Study Completion Date : July 15, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Cohort 1
Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
Drug: Pembrolizumab
200 mg, Q3W

Experimental: Cohort 2
Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
Drug: Pembrolizumab
200 mg, Q3W




Primary Outcome Measures :
  1. Efficacy of Pembrolizumab re-challenge measured by Overall Response Rate per RECIST v1.1 [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 50 months. ]
    To evaluate the efficacy of Pembrolizumab re-challenge administered 200 mg iv every 21 days in second or further line for advanced NSCLC after progression to monotherapy check point PD1 / PDL1 inhibitors measured by Overall Response Rate (ORR) per RECIST v1.1.


Secondary Outcome Measures :
  1. Efficacy of Pembrolizumab re-challenge measured by Progression Free Survival per RECIST v1.1. [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 50 months. ]
    To evaluate the efficacy of Pembrolizumab re-challenge administered 200 mg iv every 21 days in second or further line for advanced NSCLC after progression to monotherapy check point PD1 / PDL1 inhibitors measured by Progression Free Survival (PFS) per RECIST v1.1.


Other Outcome Measures:
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. [ Time Frame: From the date of the first infusion of medication until 90 days after the last dose, assessed up to 50 months. ]
    To describe the safety and tolerability profile of pembrolizumab Re-challenged as a Second or further line in previously treated patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with hystologically or cythologicalconfirmed NSCLC advanced or locally advanced disease not amenable to radical treatment (IIIA, IIIB, IV), squamous or non-squamous, recurrent after at least one prior line.
  2. The subject must be willing and able to provide written informed consent/assent for the trial.
  3. Patient must be aged ≥ 18 years of age on day of signing informed consent.
  4. Measurable disease (at least 1 lesion) based on RECIST 1.1. Patients will not be eligible if this lesion was irradiated before inclusion.
  5. Documented prior benefit (Stable Disease, Partial Response, Complete Response) to check point PD1/PDL1 inhibitor (Nivolumab, Pembrolizumab, Darvolumab, Atezolizumab, Avelumab or others) for at least 16 weeks (Stable Disease, Partial Response, Complete Response) and progression while on treatment (or <12 weeks after stopping) with the same PD-1/PD-L1 inhibitors. These patients should have received subsequent treatment with Chemotherapy for at least 4 courses (Cohort 1) OR Documented prior benefit (Stable Disease, Partial Response, Complete Response) to check point PD1/PDL1 inhibitor (Nivolumab, Pembrolizumab, Darvolumab, Atezolizumab, Avelumab or others) for at least 16 weeks (Stable Disease, Partial Response, Complete Response) and progression >12 weeks after stopping treatment (Cohort 2). No subsequent treatment before rechallenge is allowed in this cohort
  6. Patient must be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. PDL1 must be evaluable and at least 1% positive in tumor tissue. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.
  7. Have a performance status of 0-1 on the ECOG Performance Scale.
  8. Demonstrate adequate organ function, all screening labs should be performed within 7 days of treatment initiation.
  9. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  10. Female subjects of childbearing potential must be willing to use an adequate method of contraception (for the course of the study through 120 days after the last dose of study medication).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

  11. Male subjects of childbearing potential must agree to use an adequate method of contraception (starting with the first dose of study therapy through 120 days after the last dose of study therapy).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

  12. All patients will be required to submit a tumor sample for PD-L1 IHC expression. If the sample is inadequate for analysis, another sample could be provided or the patient will be considered ineligible for further randomization in the trial.

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  3. Has a known history of active TB (Bacillus Tuberculosis)
  4. Hypersensitivity to pembrolizumab or any of its excipients.
  5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.

    Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.

    Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

  7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids at a dose over 10 mg of prednisone or equivalent, for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  11. Has an active infection requiring systemic therapy.
  12. Documented EGFR sensitizing mutation.
  13. Documented ALK translocation.
  14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  16. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  19. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  20. Received radiation therapy to the lung of >30Gy within 6 months of the first dose of trial treatment.
  21. Evidence of interstitial lung disease.
  22. Has had previously serious adverse reactions (grade 3-4) related to previous PD1/PDL1 inhibitors that preclude their treatment according to the principal investigator' s criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03526887


Contacts
Layout table for location contacts
Contact: Eva Pereira +34934302006 epereira@gecp.org

Locations
Layout table for location information
Spain
Hospital General Universitario de Elche Recruiting
Elche, Alicante, Spain, 03203
Contact: María Guirado, MD         
Principal Investigator: María Guirado, MD         
H. Germans Trias i Pujol Recruiting
Badalona, Barcelona, Spain, 08916
Contact: Enric Carcereny, MD    + 34 93 430 20 06    ecarcereny@iconcologia.net   
Principal Investigator: Enric Carcereny, MD         
Hospital Parc Taulí Recruiting
Sabadell, Barcelona, Spain, 08208
Contact: Elsa Dalmau, MD         
Principal Investigator: Elsa Dalmau, MD         
Consorci Sanitari de Terrassa Recruiting
Terrassa, Barcelona, Spain, 08227
Contact: Jordi Alfaro, MD         
Principal Investigator: Jordi Alfaro, MD         
Complejo Hospitalario de la Coruña Recruiting
La Coruña, Coruña, Spain, 15006
Contact: Rosario García Campelo, MD-phD         
Principal Investigator: Rosario García Campelo         
Clínica Universidad de Navarra Recruiting
Pamplona, Navarra, Spain, 31008
Contact: Jesús Corral, MD         
Principal Investigator: Jesús Corral, MD         
Hospital de Basurto Recruiting
Bilbao, Vizcaya, Spain, 48013
Contact: Mª Ángeles Sala, MD         
Principal Investigator: Mª Ángeles Sala, MD         
Hospital de Santa Creu i Sant Pau Recruiting
Barcelona, Spain, 08025
Contact: Margarita Majem, MD         
Principal Investigator: Margarita Majem, MD         
H.U.Vall D´Hebrón Recruiting
Barcelona, Spain, 08035
Contact: Enriqueta Felip, MD    +34932746085    efelip@vhebron.net   
Principal Investigator: Enriqueta Felip, MD         
Hospital Dr. Josep Trueta Recruiting
Girona, Spain, 17007
Contact: Joaquim Bosch, MD         
Principal Investigator: Joaquim Bosch, MD         
Complejo Hospitalario de Jaén Recruiting
Jaén, Spain, 23007
Contact: Ana Laura Ortega, MD         
Principal Investigator: Ana Laura Ortega, MD         
Complejo Asistencial Universitario de León Not yet recruiting
León, Spain, 24071
Contact: Pilar Diz, MD         
Principal Investigator: Pilar Diz, MD         
Fundación Jiménez Díaz Recruiting
Madrid, Spain, 28040
Contact: Manuel Dómine, MD-phD         
Principal Investigator: Manuel Dómine, MD-phD         
H. 12 de Octubre Recruiting
Madrid, Spain, 28041
Contact: Santiago Ponce, MD-phD    +34914692313      
Principal Investigator: Santiago Ponce, MD-phD         
H. Son Llàtzer Recruiting
Palma de Mallorca, Spain, 07198
Contact: Juan Coves, MD    +34871202000 ext 1143    jcoves@sll.es   
Principal Investigator: Juan Coves, MD         
Hospital General Universitario de Valencia Recruiting
Valencia, Spain, 46014
Contact: Ana Blasco Cordellat, MD         
Principal Investigator: Ana Blasco, MD         
Hospital La Fe Not yet recruiting
Valencia, Spain, 46026
Contact: Óscar Juan, MD         
Principal Investigator: Óscar Juan, MD         
Hospital Miguel Servet Recruiting
Zaragoza, Spain, 50009
Contact: Ángel Artal, MD         
Principal Investigator: Ángel Artal, MD         
Sponsors and Collaborators
Spanish Lung Cancer Group
Investigators
Layout table for investigator information
Principal Investigator: Luís Paz Ares, MD Hospital 12 de Octubre

Additional Information:
Layout table for additonal information
Responsible Party: Spanish Lung Cancer Group
ClinicalTrials.gov Identifier: NCT03526887     History of Changes
Other Study ID Numbers: GECP 17/02_REPLAY
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: March 29, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents